Locally advanced prostate cancer: The role of surgical management

BJU International

Volumn 104, Issue 4, 2009, Pages 449-454

  Stratton, Kelly L ^a   Chang, Sam S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Locally advanced prostate cancer; Prostatectomy; Treatment outcome

Indexed keywords

BICALUTAMIDE; DOCETAXEL; ESTRAMUSTINE; FLUTAMIDE; GEFITINIB; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DRUG FATALITY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; LUNG FIBROSIS; LYMPH NODE; MALE; METASTASIS; MORBIDITY; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SURGICAL APPROACH; TREATMENT OUTCOME; HOSPITALIZATION; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; RISK FACTOR;

HUMANS; MALE; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 69849099164     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08741.x     Document Type: Review

References (23)

1. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003; 170 : S21-5
2. Denberg TD, Glode LM, Steiner JF, Crawford ED, Hoffman RM. Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma. BJU Int 2006; 98 : 335-340
3. Steuber T, Erbersdobler A, Graefen M, Haese A, Huland H, Karakiewicz PI. Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy. Cancer 2006; 106:775-782
4. Akaza H. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective - the effect of primary androgen deprivation therapy on stage C prostate cancer. BJU Int 2007; 99 (Suppl.1): 10-12
5. Smith JA Jr, Scardino PT, Resnick MI, Hernandez AD, Rose SC, Egger MJ. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol 1997; 157: 902-906
6. Meraney AM, Haese A, Palisaar J et al. Surgical management of prostate cancer: advances based on a rational approach to the data. Eur J Cancer 2005; 41: 888-907
7. Cornud F, Flam T, Chauveinc L et al. Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology 2002; 224 : 203-210
8. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 2005; 173 : 1557-1561
9. van den Ouden D, Schroder FH. Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery. World J Urol 2000; 18 : 194-203
10. Joniau S, Hsu CY, Lerut E et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 2007; 51 : 388-394
11. Van Poppel H, Vekemans K, Da Pozzo L et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 2006; 42 : 1062-1067
12. Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006; 176 : 564-568
13. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95 : 751-756
14. Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC. Radical prostatectomy for clinical stage T3a disease. Cancer 2007; 109 : 1273-1278
15. Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007; 69: 1170-1175
16. Gleave ME, Goldenberg SL, Chin JL et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166 : 500-506
17. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008; 180: 565-570
18. Vuky J, Porter C, Isacson C et al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer 2009; 115 : 784-791
19. Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003; 62 (Suppl. 1): 55-62
20. Morgan SC, Waldron TS, Eapen L, Mayhew LA, Winquist E, Lukka H. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol 2008; 88 : 1-9
21. Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-962
22. Kibel AS, Rosenbaum E, Kattan MW et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multiinstitutional pilot study. J Urol 2007; 177: 1777-1781
23. Bolla M, Collette L, Blank L et al. Longterm results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-106